Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-22-052220
Filing Date
2022-04-28
Accepted
2022-04-28 16:06:03
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm223590d2_defa14a.htm DEFA14A 16657
2 GRAPHIC tm223590d2_defa14aimg001.jpg GRAPHIC 156108
3 GRAPHIC tm223590d2_defa14aimg002.jpg GRAPHIC 116132
4 GRAPHIC tm223590d2_defa14aimg003.jpg GRAPHIC 156754
5 GRAPHIC tm223590d2_defa14aimg004.jpg GRAPHIC 78105
  Complete submission text file 0001104659-22-052220.txt   716667
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 22866478
SIC: 2834 Pharmaceutical Preparations